Paget’s Disease of Bone: Reduction of Disease Activity With Oral Risedronate
- 1 January 1998
- Vol. 22 (1) , 51-55
- https://doi.org/10.1016/s8756-3282(97)00222-6
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Comparative study of alendronate versus etidronate for the treatment of Paget's disease of boneJournal of Clinical Endocrinology & Metabolism, 1996
- Tiludronate therapy for Paget's disease of boneBone, 1995
- Comparative prospective, double‐blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of paget's disease of boneArthritis & Rheumatism, 1995
- Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myelomaBone, 1994
- Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronateJournal of Clinical Endocrinology & Metabolism, 1993
- Paget's disease of bone treated with a five day course of oral tiludronate.Annals of the Rheumatic Diseases, 1993
- Risedronate in resistant Paget's disease of boneBone and Mineral, 1992
- Treatment of paget's disease with intermittent low-dose infusions of disodium pamidronate (APD)Journal of Bone and Mineral Research, 1990
- Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonateClinical Rheumatology, 1989
- Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl)thiomethylene bisphosphonate, in the treatment of Paget's disease of boneBone, 1988